Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find Radio Compass News for 090IP5RV8F

    Client Email Product

    090IP5RV8F

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    DOSSIERs // Finished Dosage Formulations

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    DIGITAL CONTENT

    PharmaCompass
    Product SearchProduct Search
    API SUPPLIERS
    API Suppliers

    API Suppliers

    9
    US DMFs Filed

    US DMFs Filed

    0

    CEP/COS Certifications

    CEP/COS Certifications

    0

    JDMFs Filed

    JDMFs Filed

    0

    Other Certificates

    Other Certificates

    0

    Other Suppliers

    Other Suppliers

    9
    API REF. PRICE (USD / KG)
    57,881

    API Market Place

    10
    INTERMEDIATES

    0

    DOSSIERS // FDF
    USA (Orange Book)

    USA (Orange Book)

    2
    Europe

    Europe

    0

    Canada

    Canada

    0

    Australia

    Australia

    0

    South Africa

    South Africa

    0

    Uploaded Dossiers

    Uploaded Dossiers

    0

    GLOBAL SALES (USD Million)

    U.S. Medicaid

    3.00

    Annual Reports

    0

    FDF Market Place

    0

    EXCIPIENTS

    0

    PATENTS & EXCLUSIVITIES

    USFDA Orange Book Patents

    15

    USFDA Exclusivities

    4
    DIGITAL CONTENT

    Blog #PharmaFlow

    0

    News

    49
    REF STANDARD

    EDQM

    0

    USP

    0

    JP

    0

    Other Listed Suppliers

    0

    SERVICES

    0

    Full View ScreenFull Screen View
    Paratek Showing NUZYRA, Preclinical Data At ESCMID Global 2024
    Paratek Showing NUZYRA, Preclinical Data At ESCMID Global 2024

    https://www.globenewswire.com/news-release/2024/04/18/2865281/0/en/Paratek-Pharmaceuticals-Presenting-New-Data-from-NUZYRA-Omadacycline-and-Investigator-Initiated-Pre-Clinical-Studies-at-European-Society-of-Clinical-Microbiology-Infectious-Disease.html

    GLOBENEWSWIRE
    18 Apr 2024
    Share Share
    Paratek Announces Modification of BARDA Contract to Develop NUZYRA
    Paratek Announces Modification of BARDA Contract to Develop NUZYRA

    https://www.globenewswire.com/news-release/2023/07/10/2701714/33636/en/Paratek-Pharmaceuticals-Announces-Modification-of-BARDA-Contract-to-Advance-the-Development-of-NUZYRA-omadacycline-for-Post-Exposure-Prophylaxis-PEP-and-Treatment-of-Pulmonary-Anth.html

    GLOBENEWSWIRE
    10 Jul 2023
    Share Share
    EMA COMP Recommends +ve Opinion on Orphan Medicinal Product Desig. for NUZYRA
    EMA COMP Recommends +ve Opinion on Orphan Medicinal Product Desig. for NUZYRA

    https://www.globenewswire.com/news-release/2023/06/27/2695236/33636/en/European-Medicines-Agency-COMP-Recommends-Positive-Opinion-on-Orphan-Medicinal-Product-Designation-for-NUZYRA-omadacycline-for-Treatment-of-Nontuberculous-Mycobacterial-NTM-Lung-Di.html

    GLOBENEWSWIRE
    27 Jun 2023
    Share Share
    Paratek Pharmaceuticals Presenting New Data from NUZYRA
    Paratek Pharmaceuticals Presenting New Data from NUZYRA

    https://www.globenewswire.com/news-release/2023/06/12/2686254/33636/en/Paratek-Pharmaceuticals-Presenting-New-Data-from-NUZYRA-omadacycline-and-Investigator-Initiated-Research-Programs-at-ASM-Microbe-2023.html

    GLOBENEWSWIRE
    12 Jun 2023
    Share Share
    Paratek Presenting Data from NUZYRA and Investigator-Initiated Research Programs
    Paratek Presenting Data from NUZYRA and Investigator-Initiated Research Programs

    https://www.globenewswire.com/news-release/2023/04/10/2643566/33636/en/Paratek-Pharmaceuticals-Presenting-New-Data-from-NUZYRA-omadacycline-and-Investigator-Initiated-Research-Programs-at-the-European-Congress-of-Clinical-Microbiology-Infectious-Disea.html

    GLOBENEWSWIRE
    10 Apr 2023
    Share Share
    Paratek Receives $36.4 M Milestone Payment NUZYRA (omadacycline)
    Paratek Receives $36.4 M Milestone Payment NUZYRA (omadacycline)

    https://www.globenewswire.com//news-release/2023/01/05/2583662/33636/en/Paratek-Pharmaceuticals-Receives-36-4-Million-Milestone-Payment-Associated-with-the-Second-Procurement-of-NUZYRA-omadacycline-under-BARDA-Project-BioShield-Contract.html

    GLOBENEWSWIRE
    05 Jan 2023
    Share Share
    Paratek Pharma Announces Positive Top Line Data from Pilot Efficacy Study
    Paratek Pharma Announces Positive Top Line Data from Pilot Efficacy Study

    https://www.globenewswire.com/news-release/2022/12/19/2576193/33636/en/Paratek-Pharmaceuticals-Announces-Positive-Top-Line-Data-from-Pilot-Efficacy-Study-for-the-Treatment-of-Pulmonary-Anthrax-and-Acceptance-of-the-Second-Procurement-of-NUZYRA-omadacy.html

    GLOBENEWSWIRE
    19 Dec 2022
    Share Share
    Paratek Achieves Milestone Creating U.S. Mfg. Supply Chain for NUZYRA
    Paratek Achieves Milestone Creating U.S. Mfg. Supply Chain for NUZYRA

    https://www.contractpharma.com/contents/view_breaking-news/2022-10-31/paratek-achieves-milestone-creating-us-mfg-supply-chain-for-nuzyra/9769

    CONTRACTPHARMA
    31 Oct 2022
    Share Share
    Paratek Pharmaceuticals Presenting New Data for NUZYRA® (omadacycline)
    Paratek Pharmaceuticals Presenting New Data for NUZYRA® (omadacycline)

    https://www.globenewswire.com/news-release/2022/10/13/2534288/33636/en/Paratek-Pharmaceuticals-Presenting-New-Data-for-NUZYRA-omadacycline-at-IDWeek-2022.html

    GLOBENEWSWIRE
    13 Oct 2022
    Share Share
    Novasep & Paratek enhance collaboration to manufacture omadacycline (NUZYRA®)
    Novasep & Paratek enhance collaboration to manufacture omadacycline (NUZYRA®)

    https://www.novasep.com/company/media-events/press-release/novasep-and-paratek-enhance-collaboration-to-manufacture-omadacycline.html

    PRESS RELEASE
    15 Feb 2022
    Share Share
    China's National Medical Products Administration Approves NUZYRA® 
    China's National Medical Products Administration Approves NUZYRA® 

    https://www.globenewswire.com/news-release/2021/12/16/2353932/33636/en/China-s-National-Medical-Products-Administration-Approves-NUZYRA-omadacycline-for-the-Treatment-of-Bacterial-Pneumonia-and-Skin-Infections.html

    GLOBENEWSWIRE
    16 Dec 2021
    Share Share
    NMPA Approves NUZYRA as Category 1 Innovative Drug for CABP and ABSSSI
    NMPA Approves NUZYRA as Category 1 Innovative Drug for CABP and ABSSSI

    http://www.zailaboratory.com/pressnews/index.aspx

    PRESS RELEASE
    16 Dec 2021
    Share Share
    PAOG Introduces RelaxRX CBD Targeting $100 Billion Sleep Aid
    PAOG Introduces RelaxRX CBD Targeting $100 Billion Sleep Aid

    https://www.globenewswire.com/news-release/2021/10/18/2315780/0/en/PAOG-Introduces-RelaxRX-CBD-Targeting-100-Billion-Sleep-Aid.html

    GLOBENEWSWIRE
    19 Oct 2021
    Share Share
    Paratek PharmaAnnounces Enrollment of First Patient in Phase 2b Study NUZYRA®
    Paratek PharmaAnnounces Enrollment of First Patient in Phase 2b Study NUZYRA®

    https://www.globenewswire.com/news-release/2021/10/18/2316015/33636/en/Paratek-Pharmaceuticals-Announces-Enrollment-of-First-Patient-in-Phase-2b-Study-Evaluating-NUZYRA-omadacycline-for-Nontuberculous-Mycobacterial-NTM-Pulmonary-Disease-Caused-by-Myco.html

    GLOBENEWSWIRE
    18 Oct 2021
    Share Share
    Paratek Pharmaceuticals Announces Additional Funding Under the BARDA
    Paratek Pharmaceuticals Announces Additional Funding Under the BARDA

    https://www.biospace.com/article/releases/paratek-pharmaceuticals-announces-additional-funding-under-the-barda-contract-to-advance-the-development-of-nuzyra-omadacycline-for-post-exposure-prophylaxis-pep-and-treatment-of-pulmonary-anthrax/

    BIOSPACE
    27 Sep 2021
    Share Share
    Paratek Pharmaceuticals Presenting New Data for NUZYRA® (omadacycline)
    Paratek Pharmaceuticals Presenting New Data for NUZYRA® (omadacycline)

    https://www.globenewswire.com/news-release/2021/09/23/2302597/33636/en/Paratek-Pharmaceuticals-Presenting-New-Data-for-NUZYRA-omadacycline-at-IDWeek-2021.html

    GLOBENEWSWIRE
    23 Sep 2021
    Share Share
    Paratek Pharmaceuticals Announces FDA Orphan Drug Designation for NUZYRA®
    Paratek Pharmaceuticals Announces FDA Orphan Drug Designation for NUZYRA®

    https://www.globenewswire.com/news-release/2021/08/18/2283087/33636/en/Paratek-Pharmaceuticals-Announces-FDA-Orphan-Drug-Designation-for-NUZYRA-omadacycline-for-the-Treatment-of-Infections-Caused-by-Nontuberculous-Mycobacteria.html

    GLOBENEWSWIRE
    18 Aug 2021
    Share Share
    Paratek Pharmaceuticals Announces Initiation of Phase 2b Study with NUZYRA
    Paratek Pharmaceuticals Announces Initiation of Phase 2b Study with NUZYRA

    https://www.globenewswire.com/news-release/2021/06/16/2248107/33636/en/Paratek-Pharmaceuticals-Announces-Initiation-of-Phase-2b-Study-in-Nontuberculous-Mycobacterial-NTM-Pulmonary-Disease-Caused-by-Mycobacterium-abscessus-Complex-MABc-with-NUZYRA-omad.html

    GLOBENEWSWIRE
    16 Jun 2021
    Share Share
    Paratek Announces Full Year 2020 Total Revenue of $46.9 M NUZYRA®
    Paratek Announces Full Year 2020 Total Revenue of $46.9 M NUZYRA®

    http://www.globenewswire.com/news-release/2021/02/24/2181804/0/en/Paratek-Pharmaceuticals-Announces-Full-Year-2020-Total-Revenue-of-46-9-Million-including-NUZYRA-omadacycline-Net-U-S-Sales-of-38-8-Million.html

    GLOBENEWSWIRE
    24 Feb 2021
    Share Share
    Omadacycline, Moxifloxacin Similarly Effective in Legionella pneumophila
    Omadacycline, Moxifloxacin Similarly Effective in Legionella pneumophila

    https://www.firstwordpharma.com/node/1768450?tsid=5

    Nancy Melville FIRSTWORDPHARMA
    26 Oct 2020
    Share Share
    Paratek Pharmaceuticals Presenting New Data on NUZYRA®
    Paratek Pharmaceuticals Presenting New Data on NUZYRA®

    https://www.globenewswire.com/news-release/2020/10/21/2111795/0/en/Paratek-Pharmaceuticals-Presenting-New-Data-on-NUZYRA-Omadacycline-at-IDWeek-2020.html

    GLOBENEWSWIRE
    22 Oct 2020
    Share Share
    Paratek Announces Second Quarter 2020 Total Revenue of $9.3 M including NUZYRA®
    Paratek Announces Second Quarter 2020 Total Revenue of $9.3 M including NUZYRA®

    https://www.globenewswire.com/news-release/2020/08/10/2075550/0/en/Paratek-Pharmaceuticals-Announces-Second-Quarter-2020-Total-Revenue-of-9-3-Million-including-NUZYRA-omadacycline-Net-Revenue-of-8-1-Million.html

    GLOBENEWSWIRE
    10 Aug 2020
    Share Share
    Zai Lab Announces NDA for Omadacycline Granted Priority Review by China’s NMPA
    Zai Lab Announces NDA for Omadacycline Granted Priority Review by China’s NMPA

    https://www.globenewswire.com/news-release/2020/05/06/2028341/0/en/Zai-Lab-Announces-NDA-for-Omadacycline-Granted-Priority-Review-by-China-s-NMPA.html

    GLOBENEWSWIRE
    06 May 2020
    Share Share
    Paratek wins US contract to develop anthrax treatment
    Paratek wins US contract to develop anthrax treatment

    https://www.biopharmadive.com/news/paratek-barda-contract-nuzyra-anthrax-development/569461/

    BIOPHARMA DIVE
    21 Dec 2019
    Share Share
    Paratek Pharma reports positive results from phase 2 studies
    Paratek Pharma reports positive results from phase 2 studies

    http://www.pharmabiz.com/NewsDetails.aspx?aid=119131&sid=2

    PHARMABIZ
    03 Nov 2019
    Share Share
    Paratek's top antibiotic fails to clear a key competitive hurdle in head-to-head studies
    Paratek's top antibiotic fails to clear a key competitive hurdle in head-to-head studies

    https://endpts.com/parateks-top-antibiotic-fails-to-clear-a-key-competitive-hurdle-in-head-to-head-studies/

    Jason Mast ENDPTS
    02 Nov 2019
    Share Share
    Paratek +5.5% on withdrawing Europe application for Nuzyra
    Paratek +5.5% on withdrawing Europe application for Nuzyra

    https://seekingalpha.com/news/3506762-paratek-plus-5_5-percent-withdrawing-europe-application-nuzyra

    SEEKINGALPHA
    17 Oct 2019
    Share Share
    The Lancet Infectious Diseases Publishes Results Paratek’s Ph3 Oral only NUZYRA
    The Lancet Infectious Diseases Publishes Results Paratek’s Ph3 Oral only NUZYRA

    https://investor.paratekpharma.com/news-releases/news-release-details/lancet-infectious-diseases-publishes-results-parateks-phase-3

    INVESTOR
    02 Sep 2019
    Share Share
    Paratek publishes positive PhIII data on approved Nuzyra
    Paratek publishes positive PhIII data on approved Nuzyra

    https://endpts.com/paratek-publishes-positive-phiii-data-on-approved-nuzyra-allergan-settles-opioid-lawsuits-in-two-ohio-counties/

    ENDPOINT NEWS
    31 Aug 2019
    Share Share
    MMS Submission Support for Paratek Pharmaceuticals' Omadacycline
    MMS Submission Support for Paratek Pharmaceuticals' Omadacycline

    https://www.prnewswire.com/news-releases/mms-submission-support-for-paratek-pharmaceuticals-garners-fda-approval-and-successful-maa-filing-of-nuzyra-omadacycline-300728557.html

    PR NEWSWIRE
    11 Oct 2018
    Share Share
    MMS Submission Support for Paratek Pharmaceuticals' Omadacycline
    MMS Submission Support for Paratek Pharmaceuticals' Omadacycline

    https://www.prnewswire.com/news-releases/mms-submission-support-for-paratek-pharmaceuticals-garners-fda-approval-and-successful-maa-filing-of-nuzyra-omadacycline-300728557.html

    PR NEWSWIRE
    11 Oct 2018
    Share Share
    MMS Submission Support for Paratek Pharmaceuticals' Omadacycline
    MMS Submission Support for Paratek Pharmaceuticals' Omadacycline

    https://www.prnewswire.com/news-releases/mms-submission-support-for-paratek-pharmaceuticals-garners-fda-approval-and-successful-maa-filing-of-nuzyra-omadacycline-300728557.html

    PR NEWSWIRE
    11 Oct 2018
    Share Share
    Why Barnes & Noble, Paratek Pharmaceuticals, and Hortonworks Jumped Today
    Why Barnes & Noble, Paratek Pharmaceuticals, and Hortonworks Jumped Today

    https://www.fool.com/investing/2018/10/04/why-barnes-noble-paratek-pharmaceuticals-and-horto.aspx

    Dan Caplinger
    04 Oct 2018
    Share Share
    Paratek caps 20-year R&D journey with FDA OK for its broad spectrum antibiotic
    Paratek caps 20-year R&D journey with FDA OK for its broad spectrum antibiotic

    https://endpts.com/paratek-caps-20-year-rd-journey-with-fda-ok-for-its-broad-spectrum-antibiotic-time-to-talk-launch/

    Amber Tong ENDPTS
    03 Oct 2018
    Share Share
    Paratek enters commercial stage with 2 FDA antibiotics nods
    Paratek enters commercial stage with 2 FDA antibiotics nods

    https://www.fiercepharma.com/marketing/2-paratek-antibiotics-win-fda-nods-one-slated-for-500m-peak-sales

    Angus Liu FIERCE PHARMA
    03 Oct 2018
    Share Share
    Green light for acne drug Seysara in the US
    Green light for acne drug Seysara in the US

    http://www.pharmatimes.com/news/green_light_for_acne_drug_seysara_in_the_us_1254328

    Selina McKee PHARMA TIMES
    03 Oct 2018
    Share Share
    FDA Approves SEYSARA (Sarecycline) for Inflammatory Lesions of Acne Vulgaris
    FDA Approves SEYSARA (Sarecycline) for Inflammatory Lesions of Acne Vulgaris

    https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209521s000lbl.pdf

    01 Oct 2018
    Share Share
    Paratek antibiotic not inferior to current treatments: FDA staff
    Paratek antibiotic not inferior to current treatments: FDA staff

    https://www.reuters.com/article/us-paratek-pharms-fda/paratek-antibiotic-not-inferior-to-current-treatments-fda-staff-idUSKBN1KR1EY

    Tamara Mathias REUTERS
    06 Aug 2018
    Share Share
    2018 Meeting Materials, Antimicrobial Drugs Advisory Committee
    2018 Meeting Materials, Antimicrobial Drugs Advisory Committee

    FDA
    03 Aug 2018
    Share Share
    Paratek Announces FDA Advisory Committee Date for Omadacycline
    Paratek Announces FDA Advisory Committee Date for Omadacycline

    http://phx.corporate-ir.net/phoenix.zhtml?c=253770&p=irol-newsArticle&ID=2355307

    PRESS RELEASE
    20 Jun 2018
    Share Share
    Paratek Presents New Analysis from Combined Phase 3 Skin Infection Studies
    Paratek Presents New Analysis from Combined Phase 3 Skin Infection Studies

    http://phx.corporate-ir.net/phoenix.zhtml?c=253770&p=irol-newsArticle&ID=2353975

    PRESS RELEASE
    11 Jun 2018
    Share Share
    Paratek Demonstrates Breadth of Omadacycline Clinical & Microbio Data at ASM
    Paratek Demonstrates Breadth of Omadacycline Clinical & Microbio Data at ASM

    http://phx.corporate-ir.net/phoenix.zhtml?c=253770&p=irol-newsArticle&ID=2353783

    PRESS RELEASE
    07 Jun 2018
    Share Share
    Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
    Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

    http://phx.corporate-ir.net/phoenix.zhtml?c=253770&p=irol-newsArticle&ID=2352843

    PRESS RELEASE
    01 Jun 2018
    Share Share
    Paratek Presents New Analysis Highlighting Efficacy of Omadacycline
    Paratek Presents New Analysis Highlighting Efficacy of Omadacycline

    http://phx.corporate-ir.net/phoenix.zhtml?c=253770&p=irol-newsArticle&ID=2350291

    PRESS RELEASE
    22 May 2018
    Share Share
    Paratek Presents Data Supporting Potential Approval of Omadacycline
    Paratek Presents Data Supporting Potential Approval of Omadacycline

    http://phx.corporate-ir.net/phoenix.zhtml?c=253770&p=irol-newsArticle&ID=2343857

    PRESS RELEASE
    23 Apr 2018
    Share Share
    Paratek Prices $140 M of Convertible Senior Subordinated Notes due 2024
    Paratek Prices $140 M of Convertible Senior Subordinated Notes due 2024

    http://phx.corporate-ir.net/phoenix.zhtml?c=253770&p=irol-newsArticle&ID=2343472

    PRESS RELEASE
    19 Apr 2018
    Share Share
    Paratek Announces Proposed Private Offering of $125 M
    Paratek Announces Proposed Private Offering of $125 M

    http://phx.corporate-ir.net/phoenix.zhtml?c=253770&p=irol-newsArticle&ID=2343273

    PRESS RELEASE
    18 Apr 2018
    Share Share
    Paratek’s NDA for Oral & IV Omadacycline Accepted for Priority Review FDA
    Paratek’s NDA for Oral & IV Omadacycline Accepted for Priority Review FDA

    http://phx.corporate-ir.net/phoenix.zhtml?c=253770&p=irol-newsArticle&ID=2341116

    PRESS RELEASE
    04 Apr 2018
    Share Share
    Paratek Provides Update on Pipeline Progress
    Paratek Provides Update on Pipeline Progress

    http://phx.corporate-ir.net/phoenix.zhtml?c=253770&p=irol-newsArticle&ID=2324587

    PRESS RELEASE
    03 Jan 2018
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search